BASI - Bioanalytical Systems, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.0800
+0.0800 (+4.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.0000
Open2.0200
Bid1.4100 x 800
Ask3.8000 x 900
Day's Range2.0000 - 2.0873
52 Week Range1.1800 - 2.2000
Volume22,559
Avg. Volume13,032
Market Cap21.404M
Beta (3Y Monthly)1.74
PE Ratio (TTM)N/A
EPS (TTM)-0.1240
Earnings DateAug 12, 2019 - Aug 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.15
Trade prices are not sourced from all markets
  • What Kind Of Investor Owns Most Of Bioanalytical Systems, Inc. (NASDAQ:BASI)?
    Simply Wall St.

    What Kind Of Investor Owns Most Of Bioanalytical Systems, Inc. (NASDAQ:BASI)?

    The big shareholder groups in Bioanalytical Systems, Inc. (NASDAQ:BASI) have power over the company. Large companies...

  • GlobeNewswire

    BASi Continues Revenue Growth in Third Quarter of Fiscal 2019

    WEST LAFAYETTE, Ind., Aug. 14, 2019 -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We” or “Our”) today announced financial results for the three and nine.

  • GlobeNewswire

    Bioanalytical Systems to Release Third Quarter Fiscal 2019 Results on Wednesday, August 14, 2019

    Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced that it will report financial results for the third quarter of fiscal 2019 ended June 30, 2019, prior to the market opening on Wednesday, August 14, 2019. BASi is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, and various market and operating risks detailed in the company's filings with the U.S. Securities and Exchange Commission.

  • Is Bioanalytical Systems, Inc.'s (NASDAQ:BASI) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.

    Is Bioanalytical Systems, Inc.'s (NASDAQ:BASI) Balance Sheet Strong Enough To Weather A Storm?

    Bioanalytical Systems, Inc. (NASDAQ:BASI) is a small-cap stock with a market capitalization of US$21m. While investors...

  • GlobeNewswire

    Researchers Generate Better Data with BASi’s Redesigned Raturn™

    Used as an alternative to liquid swivels or commutators, the Raturn™ interactively responds to animal movement to keep wires, tubing, fluid lines, optic and electrical cables from twisting. BASi’s Raturn™ systems are used in academic research, pharmaceutical laboratories, and CROs for a wide range of applications, including in vivo microdialysis, blood collection, optogenetics, ECG studies, blood pressure, and activity monitoring. “The objective of the Raturn™ is to help researchers obtain better data by simplifying sample collection while minimizing stress to the animal,” said Lauren Elolf, PhD, BASi’s Products Business Development Manager.  “It’s a great product, but we knew we could make it even better. The Raturn™ is compatible with BASi’s current line of cage options and integrates with a number of existing products, further strengthening the Company’s portfolio to generate better data while enhancing animal welfare—all at a reasonable price.

  • GlobeNewswire

    BASi Continues Revenue Growth in Second Quarter of Fiscal 2019

    WEST LAFAYETTE, Ind., May 15, 2019 -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We” or “Our”) today announced financial results for the three and six.

  • GlobeNewswire

    Bioanalytical Systems to Release Second Quarter Fiscal 2019 Results on Wednesday, May 15, 2019

    Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced that it will report financial results for the second quarter of fiscal 2019 ended March 31, 2019, prior to the market opening on Wednesday, May 15, 2019. BASi is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, and various market and operating risks detailed in the company's filings with the U.S. Securities and Exchange Commission.

  • GlobeNewswire

    CORRECTED PRESS RELEASE: BASi Acquires the Smithers Avanza Toxicology Services Business Unit to Support Growing Toxicology Business and Broaden Scientific Talent

    This press release corrects a prior version published on May 1, 2019, and is updated to revise the amount of one of the loans previously reported. WEST LAFAYETTE, Ind., May 1, 2019 -- Bioanalytical Systems, Inc., (NASDAQ:BASI) (“BASi” or the “Company”) today announced its acquisition of the Smithers Avanza Toxicology Services business unit, a contract research organization (CRO) located in Gaithersburg, Maryland, which specializes in general toxicology, vaccine safety and developmental and reproductive toxicology (DART) studies, in support of pharmaceutical and chemical industry research and development.

  • GlobeNewswire

    BASi Acquires the Smithers Avanza Toxicology Services Business Unit to Support Growing Toxicology Business and Broaden Scientific Talent

    Bioanalytical Systems, Inc., (NASDAQ:BASI) (“BASi” or the “Company”) today announced its acquisition of the Smithers Avanza Toxicology Services business unit, a contract research organization (CRO) located in Gaithersburg, Maryland, which specializes in general toxicology, vaccine safety and developmental and reproductive toxicology (DART) studies, in support of pharmaceutical and chemical industry research and development. The acquired business will operate as a wholly owned subsidiary of BASi under the name BASi Gaithersburg.

  • Can You Imagine How Bioanalytical Systems's (NASDAQ:BASI) Shareholders Feel About The 97% Share Price Increase?
    Simply Wall St.

    Can You Imagine How Bioanalytical Systems's (NASDAQ:BASI) Shareholders Feel About The 97% Share Price Increase?

    By buying an index fund, investors can approximate the average market return. But if you pick the right individual stocks, you could make more than that. Just take a look at Bioanalytical Systems, Inc. (NASDAQ:BASI), which is...

  • Does Bioanalytical Systems, Inc. (NASDAQ:BASI) Have A Volatile Share Price?
    Simply Wall St.

    Does Bioanalytical Systems, Inc. (NASDAQ:BASI) Have A Volatile Share Price?

    Anyone researching Bioanalytical Systems, Inc. (NASDAQ:BASI) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and thereRead More...

  • GlobeNewswire

    J. Scott Daniels, PhD, Joins BASi as Senior Vice President of DMPK, Filling Key Scientific Leadership Position

    Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) is pleased to announce the addition of J. Scott Daniels, PhD, as Senior Vice President of DMPK, effective as of March 1, 2019. Dr. Daniels fills a strategic scientific leadership position within the Company that in recent months has made other key appointments to its organizational leadership following its acquisition of Seventh Wave Laboratories in July of last year.

  • GlobeNewswire

    BASi Appoints Joe Flynn as Chief Commercial Officer

    Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) is pleased to announce that Joe Flynn has been appointed as Chief Commercial Officer of the Company, effective as of February 21, 2019. Mr. Flynn will be responsible for leading sales and marketing efforts across BASi’s three sites located in West Lafayette and Evansville, Indiana, and St. Louis, Missouri. Mr. Flynn has an esteemed career as a senior executive in contract research, with over 25 years of strategic and operational experience focusing on pharmaceutical research and development.

  • GlobeNewswire

    BASi Appoints Senior Contract Research Executive, D. Thomas Oakley, as Chief Operating Officer

    Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) is pleased to announce that D. Thomas “Tom” Oakley has been appointed as Chief Operating Officer of the Company, effective as of February 11, 2019. Mr. Oakley will be responsible for leading operations among BASi’s three sites located in West Lafayette and Evansville, Indiana, and St. Louis, Missouri. Mr. Oakley is a distinguished senior executive with over 20 years of strategic and operational experience in the contract research industry.

  • GlobeNewswire

    BASi Reports Revenue Growth in First Quarter of Fiscal 2019

    WEST LAFAYETTE, Ind., Feb. 14, 2019 -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We” or “Our”) today announced financial results for the three months.

  • GlobeNewswire

    Bioanalytical Systems to Release First Quarter Fiscal 2019 Results on Thursday, February 14, 2019

    WEST LAFAYETTE, Ind., Feb. 12, 2019 -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced today that it will report financial results for the.

  • GlobeNewswire

    BASi Elects Entrepreneur, Who Has Led BASi Turnaround and Recent Growth, as President and Chief Executive Officer and a Director

    Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced the election of Robert Leasure, Jr., as President and Chief Executive Officer and as a director of the Company, effective as of January 12, 2019. Since September of 2016, Mr. Leasure has worked closely with the Company’s management team and board of directors to guide operations and assist BASi in restructuring and developing a growth strategy for the Company. Mr. Leasure’s experience leading the Company’s turnaround, including the Company’s refinancing, its acquisition of Seventh Wave Laboratories, Inc., and its execution of expansion and growth plans over the last two years, ideally positions him for the role of President and Chief Executive Officer and as a director.

  • GlobeNewswire

    BASi Continues Revenue Gains to Close Fiscal 2018

    WEST LAFAYETTE, Ind., Dec. 20, 2018 -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We” or “Our”) today announced financial results for the three and.

  • GlobeNewswire

    Bioanalytical Systems to Release Fourth Quarter and Full Year Fiscal 2018 Results on Thursday, December 20, 2018

    WEST LAFAYETTE, Ind., Dec. 18, 2018 -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced that it will report financial results for the fourth.

  • Can Bioanalytical Systems Inc (NASDAQ:BASI) Improve Its Returns?
    Simply Wall St.

    Can Bioanalytical Systems Inc (NASDAQ:BASI) Improve Its Returns?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...

  • GlobeNewswire

    BASi Names John E. Sagartz Chief Strategy Officer

    Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced the appointment of John E. Sagartz, DVM, PhD, DACVP, as the Company’s Chief Strategy Officer. Dr. Sagartz founded and led Seventh Wave Laboratories for over fifteen years prior to BASi’s acquisition of its operations in July of this year.

  • How Has Bioanalytical Systems Inc’s (NASDAQ:BASI) Earnings Fared Against The Long Term Trend
    Simply Wall St.

    How Has Bioanalytical Systems Inc’s (NASDAQ:BASI) Earnings Fared Against The Long Term Trend

    Understanding Bioanalytical Systems Inc’s (NASDAQ:BASI) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...